We advised SSI Strategy on the acquisition

Davis Polk advised SSI Strategy on its acquisition of NDA Group AB. Financial terms of the transaction were not disclosed.

Headquartered in Parsippany, New Jersey, SSI is a life sciences consultancy that combines business acumen with medical, clinical, pharmacovigilance and regulatory domain expertise to provide support to its clients. With a team of experts spanning the United States and Europe, the company works closely with drug development clients to provide an innovative and bespoke support model. In December 2020, SSI partnered with Amulet Capital Partners, a middle-market private equity investment firm focused exclusively on the healthcare sector, to fuel its expansion and grow its capabilities in adjacent life sciences functions.

Founded in 1997, NDA Group is a regulatory affairs and drug development consultancy, with 25 years of unparalleled expertise and an extensive portfolio of services through all phases of drug development. Their team of over 150 consultants and unique advisory board provide drug developers with expert regulatory advice, ensuring the safe development of complex and innovative treatments that meet the rigorous requirements of the regulatory agencies.

The Davis Polk corporate team included partners Thomas J. Malone and Harold Birnbaum and associates Steven Jaffe and Dylan Major. The sponsor finance team included partner Robert F. Smith and associates Yuko Sin and Shlomo Fink. Partner Ethan R. Goldman provided tax advice. Partner David R. Bauer provided intellectual property advice. Partner Veronica M. Wissel provided executive compensation advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post